Radiopharmaceuticals Market Value, Industry Outlook, Growth Insights, Future Trends, Analysis Report 2022-2027

According to the latest report by IMARC Group, titled "Radiopharmaceuticals Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global radiopharmaceuticals market reached a value of US$ 4.9 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2027, exhibiting a CAGR of 6.76% during 2022-2027. Radiopharmaceuticals are a group of pharmaceutical drugs that possess a high degree of radioactivity. The pharmaceutical formulations comprise radioactive isotopes, and can be delivered orally, intravenously, or interstitially. Over the past years, radiopharmaceutical therapies have emerged as one of the most efficient techniques in various areas, such as neurology, cardiology, and oncology. More convenient therapeutic radiopharmaceuticals are replacing conventional chemotherapy methods for oncology and cancer treatment, which opens new avenues in the radiopharmaceutical market. Besides this, they help physicians during diagnosis and work as a convenient and safer alternative for patients when compared to X-Rays and other external radiation imaging devices.

As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the purchase behaviors of the consumers globally-our estimates about the latest market trends and forecast values after considering the impact of this pandemic.

Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/radiopharmaceuticals-market/requestsample

Global Radiopharmaceuticals Market Trends:

The global market is primarily driven by the rising prevalence of acute and chronic diseases, such as cancer. In line with this, the increasing research and development spending on medical instruments and devices is creating lucrative growth opportunities in the market, particularly in developed and developing economies. Furthermore, extensive research and development activities in nuclear medicine are favoring the market growth. Apart from this, the growing emphasis on improving the overall quality of healthcare facilities and the healthcare infrastructure is positively influencing the market. Moreover, the numerous collaborations and strategic partnerships between public and private players in the market are creating a positive outlook for the market. Besides this, continual technological advancements enabling radiopharmaceuticals to diagnose and treat cancerous tumors are propelling the market. Additionally, various companies operating in the market are constantly focusing on the development of nuclear medicine therapies, thereby providing a boost to the market.

Ask Analyst for Instant Discount and Download Full Report with TOC & List of Figure: https://www.imarcgroup.com/radiopharmaceuticals-market

Global Radiopharmaceuticals Market 2022-2027 Analysis and Segmentation:

Competitive Landscape with Key Players:

• Advanced Accelerator Applications (Novartis AG)
• Bayer AG
• Bracco S.p.A.
• Cardinal Health Inc.
• Curium Pharma
• General Electric Company
• IBA RadioPharma Solutions
• Jubilant Pharma Limited
• Lantheus Medical Imaging Inc
• Nordion Inc. (Sotera Health)
• NTP Radioisotopes SOC Ltd
• PharmaLogic Holdings Corp.
• Siemens AG.

Breakup by Product Type:

• Diagnostic Nuclear Medicine
• Therapeutic Nuclear Medicine

Breakup by Application:

• Oncology
• Cardiology
• Neurology
• Endocrinology
• Others

Breakup by End Use:

• Hospitals and Clinics
• Research Institutes
• Diagnostic Centers

Breakup by Region:

• North America (United States, Canada)
• Europe (Germany, France, United Kingdom, Italy, Spain, Others)
• Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Key Highlights of the Report:

• Market Performance (2016-2021)
• Market Outlook (2022-2027)
• Porter's Five Forces Analysis
• Market Drivers and Success Factors
• SWOT Analysis
• Value Chain
• Comprehensive Mapping of the Competitive Landscape

If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

Other Reports of IMARC Group:

• https://icrowdnewswire.com/2022/03/31/global-meat-market-to-reach-us-1-61-trillion-by-2027-impelled-by-rising-health-consciousness-among-consumers/
• https://icrowdnewswire.com/2022/04/13/water-purifier-market-report-2022-2027-industry-top-companies-share-size-marketing-strategy-growth-statistics-and-forecast/
• https://icrowdnewswire.com/2022/04/13/gelatin-market-analysis-report-2022-2027-industry-share-future-trends-growth-opportunities-demands-and-forecast/
• https://icrowdnewswire.com/2022/04/16/3d-mapping-and-modeling-market-report-2022-2027-industry-trends-swot-analysis-top-companies-share-size-growth-and-forecast/
• https://icrowdnewswire.com/2022/05/10/marketing-automation-market-analysis-report-2022-2027-industry-growth-top-companies-share-statistics-revenue-and-forecast/

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC's information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company's expertise.

This release was published on openPR.